Wei Zhang

Dr. Wei Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LJLinkai Jing
Linkai Jing
ZQZhihong Qian
Zhihong Qian
QGQiang Gao
Qiang Gao
RSRui Sun
Rui Sun
ZZZili Zhen
Zili Zhen
WZWei Zhang
Wei Zhang

11 February 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
ZQZhihong Qian
Zhihong Qian
QGQiang Gao
Qiang Gao
WZWei Zhang
Wei Zhang
High-grade gliomas (HGG) such as glioblastoma are the most aggressive primary malignancies of the central nervous system. The median overall survival of glioblastoma is <15 months despite treatment with surgery, radiotherapy, and chemotherapy, stressing the need for additional therapeutics. Immunotherapy such as checkpoint blockade is ineffective in HGG patients owing to an immunosuppressive tumor microenvironment. Oncolytic viruses that preferentially infect and kill cancer cells represent another novel therapeutic approach and are under development for HGG treatment. We reviewed the efficacy of oncolytic viruses in HGG treatment in preclinical and clinical studies and gathered evidence suggesting the feasibility and advantage of combining oncolytic virotherapy with checkpoint blockade. We found that significant therapeutic effects of various oncolytic viruses have been validated in preclinical HGG models, but the clinical efficacy of oncolytic virotherapy alone is limited. Accumulation of tumor infiltrating lymphocytes and upregulation of immune checkpoints within tumor microenvironment following virotherapy justify the use of checkpoint inhibitors in combination with oncolytic viruses. Preliminary results indicate this combination may yield enhanced efficacy in HGG treatment. These findings suggest that oncolytic viruses combined with immunotherapy such as checkpoint blockade may have superior efficacy compared with virotherapy alone. Future studies should further assess this hypothesis using different combinations of oncolytic viruses and checkpoint inhibitors. Combined oncolytic virotherapy and immunotherapy may become an effective treatment modality to improve the survival of HGG patients.

11 September 2025 in Pediatric Investigation
Verified
Journal Article
Open access
YDYafang Deng
Yafang Deng
QGQiang Gao
Qiang Gao
WZWei Zhang
Wei Zhang
Importance: Brain and central nervous system (CNS) cancers are the most common pediatric solid tumors, significantly affecting the patients’ life expectancy and quality. Objective: To examine the disease burden of brain and CNS cancer in children and adolescents from 1990 to 2021 across various age groups, sexes, and socio‐demographic index levels, at the global, regional, and national levels. Methods: Data, including the incidence, mortality, and disability‐adjusted life years (DALYs) of brain and CNS cancer in children and adolescents, were obtained from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study. Temporal trends were evaluated using the Joinpoint regression model. The relationship between disease burden and socioeconomic development, as well as health inequality, was examined. Results: In 2021, the global age‐standardized incidence rate of brain and CNS cancers among patients aged 0–20 years was 1.55 per 100 000 population. From 1990 to 2021, the global age‐standardized mortality rate (ASMR) declined from 1.14 to 0.76 per 100 000, and the age‐standardized DALY rate (ASDR) decreased from 94.29 to 62.79 per 100 000. Over the past three decades, most regions and countries and territories have shown declining trends in ASMR and ASDR. Global inequality of disease burden persists, with regions possessing higher socioeconomic statuses exhibiting lower ASMR, ASDR, and mortality‐to‐incidence ratio. Interpretation: The decline in ASMR and ASDR of pediatric brain and CNS cancer indicates improvements in disease management and patient outcomes. Enhancing diagnostic and therapeutic strategies, improving life quality, and promoting health equity are crucial directions for future research.

29 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YXYiwei Xiao
Yiwei Xiao
MLMengyao Li
Mengyao Li
QGQiang Gao
Qiang Gao
ZQZhihong Qian
Zhihong Qian
YSYukui Shang
Yukui Shang
WZWei Zhang
Wei Zhang
Diffuse midline glioma with H3K27-altered (DMG) is a lethal pediatric malignancy that primarily occurs in the brainstem of children. In adults, DMG arising in the spinal cord is rarely reported and remains poorly understood. The cellular architecture and clinical outcomes of DMG vary depending on the tumor’s location. To dissect the genomic and transcriptional architecture of a cohort of spinal cord DMG patients, we conducted whole-exome sequencing and single-cell RNA sequencing on 19 tumor samples from 7 patients. We identified previously underappreciated stem-like cells associated with hypoxia in malignant tumor cells, which were present in all samples of spinal cord DMG but absent in published intracranial DMG, corroborating cellular heterogeneity based on tumor location. We discovered that tumor-associated myeloid cells constituted the largest population of non-malignant cells in adult spinal cord DMG. Our research revealed a transition from microglia to macrophages, characterized by enhanced cell-to-cell interactions mediated through the VEGF signaling pathway network. Notably, we found that epigenetic agents can repress the expression of hypoxia-related gene programs in patient-derived spinal cord DMG cultures and inhibit cell proliferation in vitro. Collectively, our study reveals a crucial anatomical dimension that DMG exhibits a location-specific genomic and transcriptional landscape despite shared H3K27 alterations, providing the paradigm for developing precision therapeutic strategies that extend beyond DMG to other molecularly defined yet anatomically divergent malignancies.